The U.S. Department of Defense released detailed guidelines on Wednesday outlining a new compulsory screening protocol for testosterone deficiency among active-duty and reserve service members aged 30 and above. This initiative follows an announcement made in July by U.S. Secretary of Defense Pete Hegseth.

Effective immediately, the guidance sets forth standardized screening and treatment procedures for both male and female service personnel. The Pentagon asserts that these measures are designed to enhance military preparedness by identifying and addressing hormonal and energy-related issues.

Hegseth, a proponent of testosterone use, introduced this mandate last month, sparking debates among experts regarding the scientific rationale behind such a directive. The U.S. Food and Drug Administration is planning an expert meeting in mid-September to deliberate on the medical application of testosterone.

As per the guidelines, men aged 30 and over will undergo compulsory testosterone blood tests, with younger men being tested only upon request or when clinical indications warrant it. While routine testosterone testing is not mandated for women, the guidelines recommend screening for symptoms such as fatigue and menstrual irregularities, which may indicate hormonal imbalances and conditions like low-energy availability and relative energy deficiency in sport.

The guidance also outlines the circumstances under which off-label testosterone prescription would be appropriate for women, particularly postmenopausal women experiencing abnormally low libido.

Medical professionals have expressed concerns that widespread testosterone testing could result in unnecessary or potentially harmful treatments. They argue that there is insufficient evidence to support the notion that universal screening for low testosterone among military personnel would enhance U.S. combat readiness.